cr 8

(R)-CR8 trihydrochloride (CR8, (R)-Isomer trihydrochloride) is a CDK1/2/5/7/9 inhibitor that acts as a molecular glue degrader with neuroprotective activity and induces apoptosis.

(R)-CR8 ((R)-Isomer) is a potent and selective CDK inhibitor.

(S)-CR8 is an effective second-generation cyclin-dependent kinase inhibitor.

(2S,4aR,4bS,6aS,7aS,8aS,8bS,8cR,8dR,9aR,9bR)-2,9b-Dihydroxy-4a,6a-dimethylhexadecahydro-1H-cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthren-7(7aH)-one is a useful organic compound for research related to life sciences. The catalog number is T67508 and the CAS number is 82543-16-6.

AZ084 is a potent, selective, allosteric, and orally active CCR8 antagonist (Ki: 0.9 nM) with potential to treat asthma.

GPR35 agonist 1 is a highly effective and specific GPR35/CXCR8 agonist (EC50: 5.8 nM).

LMD-009 is a non-peptide, selective CCR8 agonist that mediates chemotaxis, inositol phosphate accumulation, and calcium release, with an EC50 of 11–87 nM.

ML 145 is a selective and potent antagonist of human GPR35, with no significant activity against GPR35 in any of its immediate rodent homologs.ML 145 has potential anti-inflammatory activity for the study of immunoinflammation.ML 145 is a novel non-steroidal anti-inflammatory agent for the study of rheumatoid arthritis.

ML604086 suppresses CCL1 mediated chemotaxis and enhances intracellular Ca2 concentrations. ML604086 is a selective inhibitor of CCR8. It also inhibiting CCL1 binding to CCR8 on circulating T-cells.

OICR-8268-acrylic acid-amino-PEG9-amine is an E3 Ligase Ligand-linker conjugate. This compound is utilized for the synthesis of OICR41114.

CCR8 agonist1 (Compound 2) is an activator of CCR8 and is applicable in studies related to autoimmune diseases.

OICR-8268-acrylic acid is a ligand for E3 ubiquitin ligase. This compound can be linked to a target protein ligand via a linker to form OICR41114, which is applicable in cancer research.

pCR8 is a prodrug of CR8. It exhibits amphiphilic properties, enabling self-assembly into nanoparticles. Under high concentrations of H2O2 in the tumor microenvironment, pCR8 releases CR8. CR8 functions as a molecular glue degrader, effectively breaking down cell cycle-related proteins and possessing anti-tumor activity. pCR8 is applicable in research on cancers such as breast cancer.

LMD-902 is an analog of LMD-009 and acts as a CCR8 agonist with an EC50 of 15 nM. It exhibits excellent binding affinity, which is reliant on crucial residues such as PheVI:16. LMD-902 can be utilized in research for inflammatory conditions like bronchial asthma and central nervous system diseases such as multiple sclerosis.

R243 is CCR8 signaling and chemotaxis inhibitor.

ZK 756326 is a selective, non-peptide CCR8 chemokine receptor agonist (IC50: 1.8 μM, in human; 2.6 μM, in mouse). Displays no activity at CCR4/5 and CXCR3/4 and shows higher 28-fold selectivity over 26 other GPCRs (less selective at α2A and 5-HT receptors). Induces chemotaxis and inhibits Env-mediated (HIV) cell-cell fusion.

SB-649701 is a potent antagonist of the human CCR8 receptor, exhibiting a pIC50 value of 7.7, and is utilized in asthma research [1].

CCR8 antagonist 3 (compound 2), a potent inhibitor of CCR8, exhibits an IC 50 value of 0.062 µM and demonstrates stability in human microsomes [1].

OICR-8268 is a reversible ligand for the DCAF1 WDR domain, exhibiting a Kd of 38 nM, and facilitates the development of DCAF1-based PROTACs [1].

Anti-Flu A (H3N2) HA/Hemagglutinin Antibody (CR8043) is an antibody targeting Flu A HA/Hemagglutinin and can be used for infectious disease research.

Anti-Mouse CCR8 Antibody (C8Mab-2) is an antibody targeting CCR8 and can be used for immunology research.

Imzokitug is a humanized IgG1κ monoclonal antibody targeting CKR-L1, with its corresponding isotype control being HumanIgG1kappa, Isotype Control.

CR-8020 is a human-derived IgG1 antibody that targets the influenza A virus H3N2. It binds to the hemagglutinin (HA) of H3N2 strains, with an IC50 of 3.36 nM for A/Brisbane/10/2007 and 0.06 nM for A/Wyoming/3/2003. For isotype control, refer to HumanIgG1kappa, Isotype Control.

Anti-CCR8 Antibody (10A11) is a humanized IgG1 monoclonal antibody targeting CCR8.